PALVELLA THERAPEUTICS INC (PVLA) Stock News

USA - NASDAQ:PVLA - US6979471090 - Common Stock

62.69 USD

+0.44 (+0.71%)

Last: 9/30/2025, 8:00:01 PM

62.69 USD

0 (0%)

After Hours: 9/30/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

PVLA Latest News, Press Relases and Analysis

All

Press Releases

7 days ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin’s Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies

7 days ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin’s Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies

14 days ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy

14 days ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy

16 days ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations

16 days ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations

a month ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer

a month ago - By: Palvella Therapeutics Inc. - Mentions: ARQT

Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer

a month ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences

a month ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences

2 months ago - By: The Motley Fool

Palvella Posts Cash Gain and Trial Wins

2 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

2 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

2 months ago - By: Benzinga - Mentions: BTCM DE TIC DFLI ...

Earnings Scheduled For August 14, 2025

2 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025

2 months ago - By: Yahoo Finance - Mentions: WFC UBS MNDY CACI ...

Snap downgraded, Leidos upgraded: Wall Street's top analyst calls

2 months ago - By: Benzinga - Mentions: ALM ADAG INDV RAPP

This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

2 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

2 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

3 months ago - By: Yahoo Finance

Palvella Therapeutics Completes Enrollment for Pivotal Phase 3 Trial of QTORIN Rapamycin

3 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes

3 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes

3 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%

3 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%

3 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors

3 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors

4 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations

4 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations

4 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer

5 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

5 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

5 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

5 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

5 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025

5 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025

5 months ago - By: Yahoo Finance - Mentions: TIGO MASS VYEY AGL ...

Why Palvella Therapeutics, Inc. (PVLA) is Surging in 2025

5 months ago - By: Yahoo Finance - Mentions: GRAL ADMA CP VYEY ...

Why GRAIL, Inc. (GRAL) is Surging in 2025